X4 Pharmaceuticals Inc (XFOR)

HEALTH CARE: BIOTECHNOLOGY & LIFE SCIENCES
SIC: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)

61 NORTH BEACON STREET BOSTON, MA 02134

Arsanis, Inc. operates as a clinical-stage biopharmaceutical company. The Company focuses on applying monoclonal antibody immunotherapies to address serious infectious diseases. Arsanis serves patients in the United States and Austria.

Data as of 2021-05-08 11:52:51 -0400
Market Cap190.428 Million Shares Outstanding23.656 Million Avg 30-day Volume85.459 Thousand
P/E Ratio Dividend Yield EPS
Price/Sales Debt to Equity EBITDA
Price to Book Value0.0 Forward PE-2.35 Enterprise Value
Total Cash Current Debt Gross Profit
BETA1.30078 52-week High/Low11.11 / 5.38 Next Earnings Date2021-07-29 Price to Cash FLow (P/CF) -9999999.0
Data provided by IEX Cloud

Are you looking for this stock instead?

View SEC Filings from XFOR instead.
Q4 2020 All 13F Filers Prior Change Hedge Funds 1 Prior Change
No data found for this quarter.
1 hedge funds and active managers as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding XFOR (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding XFOR BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

4.8 Thousand total shares from 2 transactions

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

RAGAN PAULA PRESIDENT AND CEO

  • Officer
  • Director
412,752 2021-05-03 15

MOSTAFA ADAM S. CHIEF FINANCIAL OFFICER

  • Officer
112,752 2021-03-24 4

MEISNER DEREK M GENERAL COUNSEL

  • Officer
64,394 2021-03-24 3

TAVERAS ARTHUR CHIEF SCIENTIFIC OFFICER

  • Officer
8,035 2021-03-24 3

CADAVID DIEGO CHIEF MEDICAL OFFICER

  • Officer
8,035 2021-03-24 3

STEWART MURRAY

  • Director
0 2020-10-20 2

BRIDGER GARY

  • Director
0 2020-10-05 2

LAWTON ALISON FRANCES

  • Director
0 2020-10-05 2

SKERLJ RENATO CHIEF SCIENTIFIC OFFICER

  • Officer
42,076 2020-09-09 4

MCGIRR DAVID W J

  • Director
0 2020-06-10 1

RUSSO RENE

  • Director
0 2020-06-10 1

WYZGA MICHAEL S

  • Director
0 2020-06-10 1

ALISKI WILLIAM

  • Director
0 2020-06-10 1

KELLEY LYNNE E CHIEF MEDICAL OFFICER

  • Officer
0 2019-04-24 0

BLECH ISAAC

  • Director
0 2019-03-13 0

GRAY MICHAEL PRESIDENT, CEO AND CFO

  • Officer
  • Director
250,000 2018-11-27 0

SCHULMAN AMY W

  • Director
0 2018-06-05 0

GORDON CARL L

  • Director
0 2018-06-05 0

ROSS MICHAEL JAY

  • Director
0 2018-06-05 0

NESSI CLAUDIO

  • Director
0 2018-06-05 0

MCGUIRE TERRANCE

  • Director
0 2018-06-05 0

CLARK WILLIAM D

  • Director
0 2018-06-05 0

GERNGROSS TILLMAN U.

  • Director
0 2018-06-05 0

BEHBAHANI ALI

  • 10% Owner
2,000,000 2018-06-01 0

CHANG CARMEN

  • 10% Owner
2,000,000 2018-06-01 0

NAGY ESZTER CHIEF SCIENTIFIC OFFICER

  • Officer
0 2018-03-07 0

STEVENS ANTHONY CHRIS CHIEF MEDICAL OFFICER

  • Officer
0 2018-03-07 0

MANTUS DAVID CHIEF DEVELOPMENT OFFICER

  • Officer
0 2018-03-07 0

ANNA-MARIA & STEPHEN KELLEN FOUNDATION, INC.

  • 10% Owner
No longer subject to file 2017-11-20 0

EMBL TECHNOLOGY FUND II GMBH & CO. KG

EMBL VENTURES VERWALTUNGS GMBH

ADAMS JAN

HERR STEFAN

MUHLENBECK FRANK

  • 10% Owner
No longer subject to file 2017-11-20 0

NEOMED INNOVATION V L.P.

NEOMED MANAGEMENT (JERSEY) LTD

NEOMED INNOVATION V LTD

  • 10% Owner
No longer subject to file 2017-11-20 0

ORBIMED ADVISORS LLC

ORBIMED CAPITAL GP IV LLC

ISALY SAMUEL D

  • 10% Owner
1,868,966 2017-11-20 0

SECTION 32 FUND 1, LP

SECTION 32 GP 1, LLC

MARIS WILLIAM J

  • 10% Owner
No longer subject to file 2017-11-20 0

POLARIS VENTURE MANAGEMENT CO. V, L.L.C.

POLARIS VENTURE PARTNERS V, L.P.

POLARIS VENTURE PARTNERS ENTREPRENEURS' FUND V, L.P.

POLARIS VENTURE PARTNERS FOUNDERS' FUND V, L.P.

POLARIS VENTURE PARTNERS SPECIAL FOUNDERS' FUND V, L.P.

FLINT JONATHAN A

  • 10% Owner
4,844,859 2017-11-20 0

BILL & MELINDA GATES FOUNDATION

722,179 2017-11-20 0

GV 2016 GP, L.L.C.

GV 2016 GP, L.P.

GV 2016, L.P.

ALPHABET INC.

  • 10% Owner
No longer subject to file 2017-11-20 0

NEW ENTERPRISE ASSOCIATES 16, L.P.

NEA PARTNERS 16, L.P.

NEA 16 GP, LLC

  • 10% Owner
2,000,000 2017-11-20 0

BARRIS PETER J

  • 10% Owner
2,000,000 2017-11-20 0

BASKETT FOREST

  • 10% Owner
2,000,000 2017-11-20 0

FLORENCE ANTHONY A. JR.

  • 10% Owner
2,000,000 2017-11-20 0

MAKHZOUMI MOHAMAD

  • 10% Owner
2,000,000 2017-11-20 0

MOTT DAVID M

  • 10% Owner
2,000,000 2017-11-20 0

PUTTAGUNTA CHETAN

  • 10% Owner
2,000,000 2017-11-20 0

SAKODA JON

  • 10% Owner
2,000,000 2017-11-20 0

SANDELL SCOTT D

  • 10% Owner
2,000,000 2017-11-20 0

SONSINI PETER W.

  • 10% Owner
2,000,000 2017-11-20 0

VISWANATHAN RAVI

  • 10% Owner
2,000,000 2017-11-20 0

SVLSF V, LLC

SV LIFE SCIENCES FUND VI STRATEGIC PARTNERS, L.P.

SV LIFE SCIENCES FUND VI, L.P.

SV LIFE SCIENCES FUND V STRATEGIC PARTNERS, L.P.

SV LIFE SCIENCES FUND V LP

  • 10% Owner
1,868,961 2017-11-20 0

SVLSF V, LLC

SVLSF VI, LLC

SV LIFE SCIENCES FUND VI STRATEGIC PARTNERS, L.P.

SV LIFE SCIENCES FUND VI, L.P.

SV LIFE SCIENCES FUND V STRATEGIC PARTNERS, L.P.

SV LIFE SCIENCES FUND V LP

  • 10% Owner
0 2017-11-15 0

ALEXANDRIA VENTURE INVESTMENTS, LLC

  • 10% Owner
No longer subject to file 2017-11-15 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

RAGAN PAULA - Director - Officer PRESIDENT AND CEO

2021-05-04 16:11:19 -0400 2021-05-03 S 2,400 $8.33 d 412,752 direct yes 1.5 1.5 2 0.0 1

RAGAN PAULA - Director - Officer PRESIDENT AND CEO

2021-04-07 09:20:38 -0400 2021-04-05 S 2,400 $9.17 d 415,152 direct 3.1659 -2.2926 3.1659 2 -7.6419 5

MEISNER DEREK M - Officer GENERAL COUNSEL

2021-03-25 16:54:16 -0400 2021-03-24 A 47,728 a 64,394 direct -4.6995 4.4809 -12.5683 4.4809 6 -12.5683 28

CADAVID DIEGO - Officer CHIEF MEDICAL OFFICER

2021-03-25 16:56:16 -0400 2021-03-24 A 8,035 a 8,035 direct -4.6995 4.4809 -12.5683 4.4809 6 -12.5683 28

MOSTAFA ADAM S. - Officer CHIEF FINANCIAL OFFICER

2021-03-25 17:09:37 -0400 2021-03-24 A 83,163 a 112,752 direct -4.6995 4.4809 -12.5683 4.4809 6 -12.5683 28

RAGAN PAULA - Director - Officer PRESIDENT AND CEO

2021-03-25 16:55:16 -0400 2021-03-24 A 144,629 a 417,552 direct -4.6995 4.4809 -12.5683 4.4809 6 -12.5683 28

TAVERAS ARTHUR - Officer CHIEF SCIENTIFIC OFFICER

2021-03-25 17:07:11 -0400 2021-03-24 A 8,035 a 8,035 direct -4.6995 4.4809 -12.5683 4.4809 6 -12.5683 28

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

IBR Securities Loan Availability

Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

Security Date/Time Rebate Rate Fee Rate Shares Available
X4 PHARMACEUTICALS INC XFOR 2021-05-10 22:15:04 UTC -0.6421 0.6921 75000
X4 PHARMACEUTICALS INC XFOR 2021-05-10 21:45:02 UTC -0.6421 0.6921 75000
X4 PHARMACEUTICALS INC XFOR 2021-05-10 21:15:02 UTC -0.6421 0.6921 75000
X4 PHARMACEUTICALS INC XFOR 2021-05-10 20:45:03 UTC -0.6423 0.6923 75000
X4 PHARMACEUTICALS INC XFOR 2021-05-10 20:15:03 UTC -0.6423 0.6923 75000
X4 PHARMACEUTICALS INC XFOR 2021-05-10 19:45:03 UTC -0.6423 0.6923 75000
X4 PHARMACEUTICALS INC XFOR 2021-05-10 19:15:03 UTC -0.6423 0.6923 75000
X4 PHARMACEUTICALS INC XFOR 2021-05-10 18:45:03 UTC -0.6553 0.7053 75000
X4 PHARMACEUTICALS INC XFOR 2021-05-10 18:15:03 UTC -0.6553 0.7053 75000
X4 PHARMACEUTICALS INC XFOR 2021-05-10 17:45:02 UTC -0.6553 0.7053 75000
X4 PHARMACEUTICALS INC XFOR 2021-05-10 17:15:03 UTC -0.6553 0.7053 75000
X4 PHARMACEUTICALS INC XFOR 2021-05-10 16:45:03 UTC -0.6553 0.7053 80000
X4 PHARMACEUTICALS INC XFOR 2021-05-10 16:15:03 UTC -0.6553 0.7053 85000
X4 PHARMACEUTICALS INC XFOR 2021-05-10 15:45:03 UTC -0.6553 0.7053 60000
X4 PHARMACEUTICALS INC XFOR 2021-05-10 15:15:03 UTC -0.6553 0.7053 60000
X4 PHARMACEUTICALS INC XFOR 2021-05-10 14:45:04 UTC -0.6468 0.6968 60000
X4 PHARMACEUTICALS INC XFOR 2021-05-10 14:15:04 UTC -0.6468 0.6968 60000
X4 PHARMACEUTICALS INC XFOR 2021-05-10 13:45:04 UTC -0.6468 0.6968 60000
X4 PHARMACEUTICALS INC XFOR 2021-05-10 13:15:03 UTC -0.6468 0.6968 60000
X4 PHARMACEUTICALS INC XFOR 2021-05-10 12:45:02 UTC -0.6468 0.6968 55000

Current Active Short Positions

Holder Issuer Net Short Position Position Date Origin

Elevate your investments